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Oseltamivir is the main antiviral for treatment and prevention of pandemic influenza. The increase in oseltamivir resistance
reported recently has therefore sparked a debate on how to use oseltamivir in non pandemic influenza and the risks associated
with wide spread use during a pandemic. Several questions have been asked about the fate of oseltamivir in the sewage
treatment plants and in the environment. We have assessed the fate of oseltamivir and discuss the implications of
environmental residues of oseltamivir regarding the occurrence of resistance. A series of batch experiments that simulated
normal sewage treatment with oseltamivir present was conducted and the UV-spectra of oseltamivir were recorded. Findings:
Our experiments show that the active moiety of oseltamivir is not removed in normal sewage water treatments and is not
degraded substantially by UV light radiation, and that the active substance is released in waste water leaving the plant. Our
conclusion is that a ubiquitous use of oseltamivir may result in selection pressures in the environment that favor development
of drug-resistance.
Citation: Fick J, Lindberg RH, Tysklind M, Haemig PD, Waldenstro ¨m J, et al (2007) Antiviral Oseltamivir Is not Removed or Degraded in Normal Sewage
Water Treatment: Implications for Development of Resistance by Influenza A Virus. PLoS ONE 2(10): e986. doi:10.1371/journal.pone.0000986
INTRODUCTION
Influenza A virus is a zoonotic pathogen with a large environ-
mental reservoir in anatids, especially dabbling ducks [1], which
also infects a number of mammals, including pigs, horses, seals and
canines [2]. Over the past centuries, the virus has been transmitted
to humans on several occasions, causing flu pandemics and
seasonal epidemic influenzas [3]. At present, there are only few
antiviral compounds available to treat human influenza. The most
important, oseltamivir, or oseltamivir phosphate (OP), is a prodrug
that is extensively metabolized (.75%) in the human liver to
oseltamivir carboxylate (OC), the active moiety (Figure 1) [4]. OC
is not metabolized further and is excreted unchanged [4].
Oseltamivir is widely used for treatment of seasonal flu and is
considered an important first-line defense in the event of a future
influenza pandemic [5,6]. This compound is a neuraminidase
inhibitor, which mimics the natural sialic acid substrate and binds
to the active site, preventing the viral neuraminidase protein from
cleaving host-cell receptors, thereby interfering with the release of
new virus particles from infected cells [5]. To investigate whether
or not oseltamivir is removed in normal sewage water treatment,
we set up and ran batch experiments that simulated normal
sewage treatment with oseltamivir present. In these experiments,
we used OC, since this is the active moiety and also the molecule
excreted by patients.
A conventional sewage treatment plant functions in three steps:
(1) mechanical treatment, (2) chemical treatment and (3) biological
(activated sludge) treatment. In the mechanical treatment phase,
raw sewage water passes through a grid that first removes large
objects, then lipids and sand. Chemical treatment subsequently
reduces nutrients, such as phosphorus, in the aqueous phase by
addition of FeCl3 or FeSO4, while biological treatment reduces
organic content. The sludge produced is removed in the clarifiers
following each step and treated further with different techniques.
The treated water is then released and diluted into receiving water
courses.
METHODS
Experimental design
In our experiments we used three different water solutions, each
representing one of the three phases in the conventional sewage
treatment process outlined in the previous paragraph: (1) raw
sewage water, (2) water from combined mechanical/chemical
treatment, and (3) water from activated sludge treatment. All three
water solutions were collected in one liter bottles as grab samples
during two days in June 2006 at Umea ˚ Sewage Treatment Plant,
(for a detailed description of the plant, see references [7,8]. During
the two days of collecting water, normal conditions were reported
for water treatment, with some minor rainfall during the second
day. To avoid misinterpretation of the results, quantification of
OC in all the raw sewage water samples was made and additional
batch experiments (3 K h) conducted using tap water to assess
possible OC degradation or adsorption to glass walls.
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and were conducted as follows: 200 ng of OC, was added to
200 mL of each type of water and gently stirred in an open
500 mL flask at 20uC. The duration of each experiment was
determined by the hydraulic retention time in the plant: (1) raw
sewage water, 2 K h (the assumed time the water spends in the
sewage line upon reaching the sewage treatment plant); (2) water
from mechanical/chemical treatment, 1 K h; and (3) water from
activated sludge treatment, 3 K h. This approach has been used
previously with relevant and reproducible results [9]. When the
hydraulic retention time was reached, the sample was immediately
subjected to solid phase extraction (SPE) and liquid chromatog-
raphy electrospray tandem mass spectrometry (LC-ESI-MS/MS).
Each experiment was conducted in triplicate for each water
solution type to assess day-to-day variation of the sewage water
treatment process and experiments: (day 1) n=1; and (day 2)
n=2. The amount of suspended solids (SS) and pH of the various
water samples included in the batch experiments can be seen in
Table 1.
Chemicals
Oseltamivir carboxylate (OC), (RO0640802-002; lot:
01007B243804) and Oseltamivir carboxylate labelled with deute-
rium (OCD3), (RO0604802-004; lot: 511-001-2197/4) were
obtained from Roche (F. Hoffmann-La Roche Ltd, Basel,
Switzerland). Formic acid, ammonium hydroxide 25% and
methanol (HPLC-grade) were purchased from JT Baker (Deven-
ter, the Netherlands), acetonitrile (HPLC-grade) from Fischer
Chemicals (Zurich, Switzerland) and sulphuric acid from Merck
(Darmstadt, Germany). The purified water (resistivity, 18.2 MV
cm) was prepared by an ELGA MAXIMA HPLC ultra pure water
system (ELGA, High Wycombe Bucks, England), equipped with
a UV radiation source. Buffer solutions pH 5 (citric acid/sodium
hydroxid) and pH 9 (boric acid/potassium chloride/sodium
hydroxide) were bought from Merck (Darmstadt, Germany) and
were of ceripure grade. Buffer solution pH 7 (phosphate) was
purchased from JT Baker (Deventer, the Netherlands) and was of
‘‘Baker Analyzed’’ grade. Standard stock solutions of OC and
OCD3, 100 ng mL
21, were prepared in water (10 mL) and kept at
4 uC.
Solid phase extraction and quantification of OC in
sewage water
Sewage water samples were filtered through 0.45 mmM F
TM-
membrane filters (Millipore, Sundbyberg, Sweden) before acidifi-
cation to pH 3 using sulphuric acid. This low pH ensured a high
recovery of the amphoteric OC. 700 ng of the deuterated internal
standard OCD3 was added to each sample and 200 mL aliquot of
each sample was withdrawn and subjected to extraction. The
Strata-X-C (200 mg, 6 mL) mixed mode cation exchange sorbent
(Phenomenex, email: international@phenomenex.com) used for
the solid phase extraction (SPE) was conditioned and equilibrated
by 2.0 ml of methanol and 2.0 ml of deionized water. The samples
were applied to the SPE columns at a flow rate of 5 mL min
21.
Impurities were removed by 2.0 ml 0.1% sulphuric acid and the
sorbents dried with air during 1 min at 10’’ Hg. Supposed neutral
and acidic components were removed by 2 mL of methanol and
wasted, followed by elution of the analytes by 2 mL of 5%
NH4OH in methanol collected with 10 ml glass vials. The eluates
were evaporated to approximately 20 ml using air and then
reconstituted in acetonitrile in water (1:1), containing 0.1% formic
acid, to a final extract volume of 1.0 ml. Quantification of OC was
performed by internal standard calibration by comparison of area
ratios OC/OCD3 in sample extracts and calibration solution.
Liquid chromatography electrospray tandem mass
spectrometry
A1 0ml aliquot of sample extracts and calibration solutions was
injected into a YMC Hydrosphere C18 analytical column,
15064.6 mm i.d., 5 mm particle size, (YMC Inc., Wilmington,
NC, US) following a 1064 mm i.d., 5 mm particle size, YMC
Hydrosphere C18 guard column using an AS 3000 autoinjector
(Thermo Finnigan, San Jose, CA, US). OC and OCD3 were
chromatographically separated during 5 min by 50% H20
balanced with acetonitrile, both containing 0.1% (v/v) formic
acid, at a flow rate of 0.8 ml min
21 generated by a P4000 HPLC
pump (Spectra system, Thermo Finnigan) at 25uC.
An LCQ Duo ion trap mass spectrometer (Thermo Finnigan)
was used together with an electrospray ion source in positive ion
mode. The source voltage was maintained at a constant 6.0 kV
and the heated capillary temperature set to 250uC. The MS/MS
parameters were optimised semi-automatically for the analytes
Figure 1. Oseltamivir phosphate (OP), oseltamivir carboxylate (OC), the internal standard (IS) used, and deuterated oseltamivir carboxylate
(OCD3).
doi:10.1371/journal.pone.0000986.g001
Table 1. pH and suspended solids (SS) of the water included
in the batch experiments
......................................................................
pH SS
mg/L
day 1 day 2 day 1 day 2
RSW
a 8,05 7,60 290 170
mech/chem
b 7,66 7,47 510 570
AST
c 7,65 7,31 2700 2800
aRaw sewage water.
bWater from mechanical/chemical treatment.
cWater from activated sludge treatment
doi:10.1371/journal.pone.0000986.t001
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PLoS ONE | www.plosone.org 2 October 2007 | Issue 10 | e986using LCQ Duo internal software whilst the collision energy, to
produce daughter ions, was manually optimised.
For OC and OCD3 parent and daughter ion m/z, collision
energy, retention time, extraction yields in tap water and raw
sewage water and LOQ, see Table 2.
The m/z obtained for the OC and OCD3 parent and daughter
ions are consistent with those reported by Wiltshere et al. [10] who
also identified that the resultant daughter ion (M
+ -88 amu) had
lost the pentyloxy sidechain. The retention time of the deuterated
intermal standard, OCD3, was analogous to OC, and the linearity
of the calibration curve was above 0.99. Memory effects during
LC-ESI-MS/MS were not observed. The extraction yields OC
with the mixed mode cation exchange sorbent were in most cases
close to 100%, regardless of matrix subjected to extraction, and
the precision was acceptable with RSD below 21%. Breakthrough
effects were not observed at any level of sample load volume used,
and sequential elutions (362 mL) with MeOH or NH4OH did not
contain OC above LOQ. Extraction yields of the internal standard
OCD3 were not determined but assumed to be analogous to OC
due to their similarity in physico/chemical properties.
Method validation
Extraction yields of OC were assessed by fortification experiments.
1000 ng of OC was added to the following matrices prior to
extraction with the method presented above (in mL): tap water-10,
100 and 500; and raw sewage water (filtered through 0.45 mm)-10,
100, 200 (n=3) and 500. OCD3, 700 ng, were added to the
reconstituted extracts (1 mL during these experiments) prior to
injection on the LC-ESI-MS/MS. The extraction yields were
evaluated by comparison of LC-ESI-MS/MS peak area ratios of
OC/OCD3 insample extracts againsta calibrate solution of 1000 ng
mL
21 of OC in 1 mL acetonitrile in water (1:1), 0.1% formic acid.
Evaluation ofmatrixeffects during LC-ESI-MS/MSwasassessed by
comparison of the OCD3 peak area in chromatograms of the
calibrate solution and the sample extracts of the following degree of
enrichment during SPE: 0, 10, 100, 200, and 500 times.
An internal standard calibration curve of eight levels, 1–
1000 ng mL
21, of OC was injected into the LC-ESI-MS/MS.
The limit of quantification (LOQ) was evaluated by using ten
times the signal to noise ratio of OC, 1000 ng mL
21 in sample
extract (enriched 200 times).
Blank samples of tap water and raw sewage water subjected to
SPE and acetonitrile in water (1:1), containing 0.1% formic acid,
were regularly injected into the LC-ESI-MS/MS to control and
reduce potential memory effects.
Ultraviolet absorption spectra
Standard solutions of OC (10
23 M, 284,35 mg l
21) were prepared
in buffer solutions with pH 5, 7 and 9. UV-spectra were recorded on
a UV-VIS-NIR scanning spectrophotometer (UV-3101PC, Shi-
madzu), which was set to scan over 250–800 nm. To correct for
differences in cell performance, a baseline correction was made with
corresponding buffer solution in both sample and reference cells.
RESULTS
No OC was detected in the raw sewage water and no losses
observed in the batch experiment using tap water, which
minimizes the possibilities of positive or negative sampling
artefacts. OC and OCD3 were readily affected by matrix
components in the raw sewage water (Figure S1). However, the
combination of a high recovery of OC during solid phase
extraction of sewage water, and the use of a deuterated internal
standard with almost identical physico-chemical properties, makes
the developed analytical methodology very suitable for environ-
mental monitoring in various aqueous matrices.
Removal of OC due to degradation and/or sorption to sludge
was not observed in the batch experiments. The day-to-day
variation in terms of batch experiment and treatment process
seemed to be minor, and all results are close to a 100% recovery of
the added OC in the aqueous phase (Figure 2). Recoveries were
107% (S.D. 19) in the raw sewage water, 126% (S.D. 8) in the
water from combined mechanical/chemical treatment, and 125%
(S.D. 27) in the water from activated sludge treatment.
These findings suggest that, since OC is not removed during
sewage treatment, it will enter local aquatic environments in areas
where oseltamivir is prescribed to patients for therapeutic use.
Table 2. LC-ESI-MS/MS parameters and results of the method validation.
..................................................................................................................................................
PI
a CE
b DI
c tr Extraction yield % LOQ
m/z % m/z min 10 mL
d 100 mL
d 200 mL
e 500 mL
d ng/L
OC 284.9 21 196.9 1.97 114/107 97/100 90 (10) 107/91 15
OCD3 287.9 20 199.9 1.96 - - - - -
aParent ion.
bCollision energy, arbitrary unit.
cDaughter ion.
dRaw sewage water/tap water.
eCumulative mean and RSD in % (in parenthesis) of three SPEs and three injections, respectively, on LC-ESI-MS/MS.
doi:10.1371/journal.pone.0000986.t002
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Figure 2. Results of batch experiments to assess removal of
oseltamivir carboxylate (OC) from the aqueous phase during
conventional sewage water treatment. Shown is the OC remaining
in the aqueous phase after the batch experiments. Abbreviations: RSW,
raw sewage water; mech/chem., mechanical and chemical treatment of
sewage water; and AST, activated sludge treatment of sewage water.
White and grey bars represent day 1 and day 2 of the batch
experiments, respectively.
doi:10.1371/journal.pone.0000986.g002
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PLoS ONE | www.plosone.org 3 October 2007 | Issue 10 | e986A way to estimate the levels in the aquatic environment is to
calculate the highest predicted environmental concentration (PEC)
according to,
PEC mg=l ðÞ ~
A| 100   R ðÞ
365|P|V|D|100
where A is the total actual pharmaceutical sales (mg year
21), R the
removal rate due to loss by adsorption to sludge particles,
volatilization, hydrolysis or biodegradation (%), P the human
population (number of individuals), V the volume of wastewater
per capita per day (l day
21) and D a factor for dilution of waste
water by surface water flow.
The country where oseltamivir is used most is Japan [11],
Roche estimates that 6 million of the 16 million Japanese
individuals infected by an influenza virus during the influenza
season 2004/2005 received oseltamivir [12]. Environmental
concentrations should therefore be the highest in Japan, with the
calculated PEC value equal to PECsurfacewater_Japan=0.028 mgl
21
where A=2650 kg (Estimated volume during flu season 2004/
2005)
12 (Estimation is based on 30% pediatric dosage, 70% adult
dosage and OP converted to OC), R=0 (No removal), P=127
417 244 (2005), V=200 (Default) and D=10 (Default). This
calculation provides a national annual average and does not
consider local factors such as catchment size, population density or
flow rates. Another factor not included is seasonal consumption,
such as increased usage during flu season. This PEC level can be
compared to the IC50 (concentration that causes 50% inhibition)
of OC, which depends heavily on type of virus and exposure system,
but such low levels as 0.28–0.81 nM (IC50)h a v eb e e nr e p o r t e d
[11,13]. This corresponds to a concentration of 0.08–0.23 mgL
21,
i.e. a concentration of the same magnitude as the calculated PEC
value. Singer et al. [14] estimated the environmental levels of OC
during treatment and prevention of a pandemic influenza in Europe
and North America. Estimations showed that environmental levels
would differ significantly between different catchments and
maximum concentrations would range from,0,3 mgL
21 to 32 mg
L
21. Predicted levels in Japan during the flu season are thus
comparable to predicted levels in some catchment areas during
treatment and prevention of a pandemic.
Incidentally, Japan also has high rate of emerging resistance to
oseltamivir [15]. Kiso et al. [16] reported that 18% (9 patients) of
the influenza A virus in children had mutations that made them
300–10
5 times more resistant to oseltamivir.
Once a pharmaceutical enters the aquatic environment, photo-
chemical degradation represents another possible degradation
pathway [17]. However, the UV-spectra of OC show no absorbance
in the interval 295–700 nm, which excludes direct aqueous photolysis
as a major degradation pathway. Only chemicals that are able to
adsorb solar radiation can be degraded and solar radiation in
wavelengths shorter than 290–300 nm does not reach the Earth’s
surface, see Figure 3, and radiation with wavelengths.700 nm do
not contain enough energy to break bonds within the molecules.
Pharmaceuticals in the aquatic environment are primarily
removed by three degradation pathways: sorption, biodegradation
and photolysis. Our experimental results show that OC is not
readily degraded by any of these three, which implies that OC is
released into aquatic environments at varying concentrations and
is not readily removed. Thus, ducks, poultry and humans, or their
excretions carrying influenza viruses, may encounter water
contaminated with oseltamivir. Under these circumstances, where
influenza viruses come in contact with low concentrations of the
drug, the stage is set for the evolution of oseltamivir-resistant
influenza strains [1].
DISCUSSION
The problem of environmental contamination becomes even more
serious when one considers the ecology of influenza A virus. The
life cycle of influenza A virus is intrinsically linked to water where
they can remain active for extended periods; and under cold
conditions for months [18–20].Mostsubtypes circulate inwildducks
[1] that become infected by contaminated water establish infection
inthe gastrointestinal tract,wherethe virus multipliesand isexcreted
in large numbers via the faeces [2,21]. Thus, both the infection and
the pharmacological effect of OC occur in the gastrointestinal tract.
Due to the poor bioavailability of OC [4] it is therefore theoretically
possible that exposed ducks have OC at levelsclose tothe IC50inthe
gastrointestinal tract and that this could promote a selection process
towards drug-resistance. Singer and coworkers recently stated this
was a potential risk during treatment and prevention of a pandemic
influenza [14], and our calculations imply that this can also be
a potential risk in Japan today.
In some localities, wild ducks, domesticated ducks, poultry and
humans all live in close proximity, transmit influenza viruses to
each other, and conceivably ingest low concentrations of OC in
treated or untreated sewage water. The water outside a sewage
plant may comprise a particularly high risk microhabitat where
ducks carrying a multitude of influenza virus strains encounter low
levels of oseltamivir. This is particularly so because large numbers
of ducks often gather in the warm nutrient-rich waters leaving
sewage treatment plants, especially in cold climates where this
warmer water remains ice-free year-round.
In some parts of the world, chicken manure is used as fertilizer
in fish farming, a practice that can increase the spread of avian
influenza [22]. During an outbreak of avian influenza in poultry,
this activity could expose ducks, and other animals frequenting fish
ponds downstream from sewage outlets, to highly pathogenic
influenza virus strains from the chickens and low concentrations of
OC from sewage water
Studies have shown that most oseltamivir resistant strains
detected so far, have been detected in patients not treated with
oseltamivir [11,23]. It remains to be seen if such resistant strains
are transmitted from treated individuals, the result of natural
variation in the absence of oseltamivir altogether, or due to the
selective pressure of low doses of oseltamivir in the environment.
Previous research has, however, shown that it is quite easy for
influenza A virus to develop resistance to oseltamivir [24,25]. For
example, a single amino acid substitution, from histidine to
tyrosine at position 274 (N2 numbering system; N2 numbering is
used throughout this article) of the neuraminidase gene ‘‘con-
verted’’ an oseltamivir sensitive H5N1 influenza A virus into
a resistant strain, with about a 400–600-fold higher resistance to
Figure 3. UV-spectra of oseltamivir carboxylate, at pH 5, 7, 9 and
atmospheric transmission at sea level (expressed on a scale of 0 to 1).
doi:10.1371/journal.pone.0000986.g003
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neuraminidase gene leading to amino acid substitutions pre-
dominantly at positions 119, 152, 274 and 292 of the enzyme’s
active site [5]. All the resistant variants thus far have contained
specific mutations in the neuraminidase molecule; but since
neuraminidase serves an essential purpose, mutations that allow
the virus to ‘‘survive’’ must not inactivate the enzyme [15]. Carr et
al. [26] showed, for example, that mutations at position 292
compromised viral fitness to such extent that it was considered to
have no clinical consequences. However, an experimental study in
ferrets [27] has shown that mutations at position 119 do not
compromise viral fitness. The authors state that ‘‘if such viruses are
transmitted, it is uncertain whether, over time, they could
predominate over susceptible strains’’ [27].
In conclusion, our experimental results, theoretical calculations
and hypothesis imply the possibility that ubiquitous use of
oseltamivir may result in selection pressures in the environment
that favor development of drug-resistance. This raises the all-
important question as to whether or not such a risk should be
taken, or if a more restricted use of these agents should be
advocated? This is an opinion shared by other researchers [28],
and we would like to add that the effects of pharmaceuticals
continuously released into the environment should not be
underestimated and certainly investigated carefully before wide-
spread use of a drug is encouraged.
SUPPORTING INFORMATION
Figure S1 Peak area of OCD3 in calibrate solution and in raw
sewage water (RSW) extracts, as a function of enrichment 10, 100,
200, and, 500 times during SPE.
Found at: doi:10.1371/journal.pone.0000986.g003 (0.54 MB TIF)
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